Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

86 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma.
Erwin WD, Spies SM, Kelly ME, Rao P, Eckersberg-Rhodes TE, Nannapaneni M, Groch MW. Erwin WD, et al. Nucl Med Commun. 2001 Feb;22(2):247-55. doi: 10.1097/00006231-200102000-00018. Nucl Med Commun. 2001. PMID: 11258413 Clinical Trial.
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-López AJ. Wiseman GA, et al. Eur J Nucl Med. 2000 Jul;27(7):766-77. doi: 10.1007/s002590000276. Eur J Nucl Med. 2000. PMID: 10952488 Clinical Trial.
86 results